IO Biotech Provides Corporate Update
Globe Newswire (Fri, 30-Jan 8:05 AM ET)
IO Biotech to Explore Strategic Alternatives: What’s Behind This Major Shift?
Market Chameleon (Thu, 22-Jan 6:14 AM ET)
IO Biotech Announces Exploration of Strategic Alternatives
Globe Newswire (Wed, 21-Jan 5:30 AM ET)
Market Chameleon (Mon, 20-Oct 6:32 AM ET)
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Io Biotech trades on the NASDAQ stock market under the symbol IOBT.
As of April 16, 2026, IOBT stock price was flat at $0.05 with million shares trading.
IOBT has a beta of -1.58, meaning it tends to be less sensitive to market movements. IOBT has a correlation of 0.01 to the broad based SPY ETF.
IOBT has a market cap of $3.45 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, IOBT traded as high as $2.79 and as low as $.03.
IOBT has underperformed the market in the last year with a return of -94.6%, while the SPY ETF gained +31.8%. In the last 3 month period, IOBT fell short of the market, returning -90.7%, while SPY returned +1.6%. However, in the most recent 2 weeks IOBT has outperformed the stock market by returning +9.8%, while SPY returned +7.1%.
IOBT support price is $.04 and resistance is $.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IOBT shares will trade within this expected range on the day.
